|
|
|
|
MolDrug AI Systems has been named among APTE’s Top 100 Startups 2025. This recognition highlights the company’s work in developing computational and data-driven approaches that support molecular research and the identification of bioactive compounds in early discovery stages.
|
|
|
Read more in the complete article
|
|
In 2025, MolDrug AI Systems was named among APTE’s Top 100 Startups 2025, recognising its consolidation and growing role within the biotech landscape. In the same year, the company also joined several established networks, including BIOVAL, AseBio, and Microbionet, strengthening its presence and engagement across the life sciences sector.
|
|
|
Take a look at MolDrug AI Systems’ latest scientific publications, (with link to directly access):
|
|
MolDrug, together with its associated company ProtoQSAR has appeared in several media outlets, including Diario Siglo XXI, El Periodista Digital, and El Confidencial Digital, among others. These articles highlight MolDrug’s consolidation as a knowledge-based company, its sustained growth, and its activity in computational chemistry, molecular modelling, and AI-driven tools for drug discovery.
|
|
|
A look back at MolDrug’s events:
|
|
SEQT Summer School on Drug Discovery · Bilbao
MolDrug took part in the Sociedad Española de Química Terapéutica (SEQT) Summer School with the participation of our researcher Laureano E. Carpio and our PhD student Carmen Ortiz, engaging in discussions on medicinal chemistry and computational approaches to drug discovery.
|
|
|
XLII Annual Meeting of the Spanish Society of Pharmacology · Valencia
MolDrug took part in the annual meeting of the Spanish Society of Pharmacology, where our researcher Martina Palomino and our PhD student Idoia Álvarez presented their research on the prediction of toxic properties of mycotoxins and metabolomics.
|
|
|
EUROPIN Summer School · Vienna
Our researcher, Laureano E. Carpio, attended the EUROPIN Summer School, taking part in training and scientific exchange focused on drug discovery and computational approaches.
|
|
|
|
BioSpain 2025 · Barcelona
MolDrug took part in BioSpain 2025, with Rafael Gozalbes, Simón Perera, and our researcher Martina Palomino representing the company and connecting with the biotech ecosystem.
|
|
|
Did you know that researchers from Tsinghua University and Peking University have developed DrugCLIP, an computer-driven virtual screening platform capable of evaluating over 10 trillion protein–molecule pairs in a single day? Recently published in Science (2026), this approach combines contrastive learning and dense retrieval to overcome one of the main bottlenecks of traditional docking methods: the massive computational cost of large-scale virtual screening. Using this strategy, the authors screened 10,000 human proteins against 500 million compounds, generating more than 2 million candidate hits and experimentally validating ligands for clinically relevant targets. Advances like this highlight how in silico approaches are becoming essential for rapid compound prioritization, time reduction, and smarter use of computational resources, fully aligned with modern drug discovery workflows that integrate docking, molecular modeling, and machine learning.
|
|
|
|
Don’t miss MolDrug’s upcoming events:
|
|
|
To get in touch before de event, write to: info@moldrug.com
|
|
|
Thank you for staying connected with MolDrug.
Please share this newsletter with colleagues who may be interested.
|
|
|
|
|
|
|
